Nadia Giannetti
A5075925255- Transplantation: Methods and Outcomes
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Renal Transplantation Outcomes and Treatments
- Cardiac pacing and defibrillation studies
- Cardiac Structural Anomalies and Repair
- Mechanical Circulatory Support Devices
- Viral Infections and Immunology Research
- Diabetes Treatment and Management
- Cardiac Valve Diseases and Treatments
- Cardiomyopathy and Myosin Studies
- Organ Transplantation Techniques and Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Medication Adherence and Compliance
- Cardiovascular Issues in Pregnancy
- Chronic Disease Management Strategies
- Cardiac Health and Mental Health
- Hepatitis C virus research
- Organ and Tissue Transplantation Research
- Antibiotics Pharmacokinetics and Efficacy
- Cardiac Imaging and Diagnostics
- Cardiac Arrest and Resuscitation
- Hormonal Regulation and Hypertension
- Climate Change and Health Impacts
- Cardiac Arrhythmias and Treatments
McGill University
2014-2025
McGill University Health Centre
2015-2024
Royal Victoria Hospital
2006-2023
Institute for Molecular Medicine Finland
2022
Inserm
2022
Université de Lorraine
2022
French Clinical Research Infrastructure Network
2022
Copenhagen University Hospital
2022
Rigshospitalet
2022
Tufts Medical Center
2022
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless presence or absence diabetes. More evidence is needed regarding effects these drugs across broad spectrum failure, including those with a markedly reduced ejection fraction.
Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with and a reduced ejection fraction, but their effects preserved fraction are uncertain.
Abstract Aims In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether benefits empagliflozin varied by baseline health status and how impacted patient-reported outcomes in patients with heart failure reduced ejection fraction. Methods results Health was assessed Kansas City Cardiomyopathy Questionnaires-clinical summary score (KCCQ-CSS). The influence KCCQ-CSS (analyzed tertiles) on effect major examined using Cox proportional hazards models. Responder analyses...
Clostridium difficile-associated diarrhea (CDAD) is an increasingly important diagnosis in solid organ transplant recipients, with rising incidence and mortality. We describe the incidence, risk factors, outcomes of colectomy for CDAD after transplantation.Patients were identified from a prospective database. Complicated difficile colitis (CCDC) was defined as associated graft loss, total colectomy, or death.From 1999 to 2010, we performed transplants 1331 recipients at our institution. The...
EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure preserved ejection fraction (HFpEF). This report describes baseline characteristics cohort and compares them enrolled prior HFpEF trials. a phase III randomized, international, double-blind, parallel-group, placebo-controlled which 5988 symptomatic [left ventricular (LVEF) >40%] without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to elevated N-terminal...
<h3>Importance</h3> The period following heart failure hospitalization (HFH) is a vulnerable time with high rates of death or recurrent HFH. <h3>Objective</h3> To evaluate clinical characteristics, outcomes, and treatment response to vericiguat according prespecified index event subgroups from HFH in the Vericiguat Global Study Subjects With Heart Failure Reduced Ejection Fraction (VICTORIA) trial. <h3>Design, Setting, Participants</h3> Analysis an international, randomized,...
Women and men with heart failure (HF) preserved ejection fraction may differ in their clinical characteristics response to therapy. The aim of this study was evaluate the influence sex on effects empagliflozin patients HF enrolled EMPEROR-Preserved trial (Empagliflozin Outcome Trial Patients With Chronic Heart Failure Preserved Ejection Fraction).The primary outcome cardiovascular death or hospitalization for secondary outcomes (including total hospitalization, all-cause mortality, Kansas...
Quality of life (QoL) is an important end point in heart failure (HF) studies. The Minnesota Living with Heart Failure questionnaire (MLHFQ) the instrument most widely used to evaluate QoL patients. It a containing 21 questions scores ranging from 0 105. A best cut-off value for MLHFQ identify those patients good, moderate or poor has not been determined.To determine score based on neural network (NN) approach. These will help discriminate between HF having QoL.This research was carried out...
Background: The pathophysiology of heart failure with preserved ejection fraction is not well understood, but evidence strongly suggests involvement microvascular dysfunction. We studied the myocardial oxygenation reserve as a direct marker coronary vascular function and its relation to deformation tissue characteristics by cardiovascular magnetic resonance (CMR). Methods: In dual-center case-control study, patients (>50%) healthy controls older than 50 years underwent quantitative CMR...